Blueprint Medicines (BPMC) CEO Jeff Albers on Q4 2018 Results - Earnings Call Transcript [Seeking Alpha]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Seeking Alpha
Blueprint Medicines (BPMC) CEO Jeff Albers on Q4 2018 Results - Earnings Call Transcript Blueprint Medicines (NASDAQ: BPMC Company Participants Jim Baker - Vice President, Corporate Affairs Jeff Albers - Chief Executive Officer Kate Haviland - Chief Operating Officer Andy Boral - Chief Medical Officer Mike Landsittel - Chief Finance Officer Conference Call Participants Jason Jakoby - Goldman Sachs Marc Frahm - Cowen and Company Arlinda Lee - Canaccord Charles Zhu - Guggenheim Partners Operator Good day, ladies and gentlemen, and welcome to the Q4 2018 Blueprint Medicines Corporation Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call maybe recorded. I would now like to introduce your host for today's conference, Mr. Jim Baker of Blueprint Medicines. Sir, you may begin. Thank you, operator. Good morning. Welco
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Citigroup Inc. from $65.00 to $76.00. They now have a "sell" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at JMP Securities from $114.00 to $125.00. They now have a "market outperform" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at HC Wainwright from $125.00 to $135.00. They now have a "buy" rating on the stock.MarketBeat
- Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $70.00 to $75.00. They now have an "equal weight" rating on the stock.MarketBeat
BPMC
Earnings
- 5/2/24 - Beat
BPMC
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 144
- 5/2/24 - Form 144
- BPMC's page on the SEC website